FOXBORO, Mass. – Cyberkinetics Neurotechnology Systems Inc. (OTCBB: CYKN) today announced it has applied to the U.S. Food and Drug Administration for permission to market its implantable Andara OFS nerve-growth stimulation system, under a humanitarian waiver. Approval would make the Andara the first such device on the market. Its oscillating electrical field is designed to…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.